Unia Europejska - polski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - czerniak - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Unia Europejska - polski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - Łuszczyca - leki immunosupresyjne - treatment of moderate-to-severe plaque psoriasis in adults.